[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,76,109,133,170,192,218,242,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100512874","phase-1-ima402-t-cell-engaging-receptor-molecule-tcer-in-recurrent-andor-refractory-solid-tumors-100512874",false,"NCT05958121","IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and\u002For Refractory Solid Tumors","A Phase I\u002FII First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and\u002For Refractory Solid Tumors","Inclusion Criteria:\n\n* Patients ≥ 18 years old\n* Patients must have a specific pathologically confirmed and documented advanced and\u002For metastatic solid tumor indication\n* Patients must have received or not be eligible for indicated standard-of-care treatments per cohort\n* Measurable disease according to RECIST 1.1\n* Confirmed HLA status\n* ECOG Performance Status of 0 to 1\n* Adequate baseline hematologic, hepatic and renal function, acceptable coagulation status\n\nExclusion Criteria:\n\n* Other active malignancies that require treatment or that might interfere with the trial endpoints\n* The patient is pregnant or is breastfeeding\n* History of hypersensitivity to components of IMA402 or rescue medications; hypersensitivity to or contraindication according to current SmPC for respective combination medicinal product\n* The patient has concurrent severe and\u002For uncontrolled medical disease. Any other health condition that would, in the investigator's or sponsor's judgement, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures\n* Patients with active brain metastases, history of bleeding into brain metastases, known brain metastases who are receiving therapeutic anticoagulation","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and\u002For refractory solid tumors.\n\nPrimary objectives:\n\n* To determine the maximum tolerated doses and\u002For recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia)\n* To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I\u002FII)\n* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)\n\nSecondary objectives:\n\n* To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I)\n* To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II)\n* To describe the PK of IMA402 as monotherapy and in combination (Phase I\u002FII)",[27,28,29,30],"Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2023-08-09",{"date":39,"type":20},"2027-09",{"name":41,"class":42},"Immatics Biotechnologies GmbH","INDUSTRY",29,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100338413","phase-1-actengine-ima203ima203cd8-as-monotherapy-or-in-combination-with-nivolumab-in-recurrent-andor-refractory-solid-tumors-100338413","NCT03686124","ACTengine® IMA203\u002FIMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and\u002For Refractory Solid Tumors","Phase 1\u002F2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer\u002FGermline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and\u002For Refractory Solid Tumors","ACTengine","Inclusion Criteria:\n\n* Patients must have recurrent\u002Fprogressing and\u002For refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* HLA-A\\*02:01 positive\n* For patients with ovarian\u002Ffallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.\n* For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma.\n* Measurable disease according to RECIST 1.1\n* Adequate selected organ function per protocol\n* Patient's tumor must express tumor antigen by \"IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.\n* Life expectancy more than 5 months\n* Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203\u002FIMA203CD8\n* Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203\u002FIMA203CD8\n* The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.\n\nExclusion Criteria:\n\n* History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years\n* Pregnant or breastfeeding\n* Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.\n* History of cardiac conditions as per protocol\n* Prior stem cell transplantation or solid organ transplantation\n* Concurrent severe and\u002For uncontrolled medical disease that could compromise participation in the study\n* History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician\n* Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.\n* Patients with LDH greater than 2.0-fold ULN.\n* Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and\u002For IMA203\u002FIMA203CD8 treatment\n* Patients with active brain metastases\n* Concurrent treatment in another clinical trial.\n* For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1\u002FPD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).\n\nOther protocol defined inclusion\u002Fexclusion criteria could apply",{"count":53,"type":20},375,[23,24],"The study's purpose is to establish the safety and tolerability of IMA203\u002FIMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).",[27,28,29,30],[58,59,60,61,62,63,64,65],"T-cell therapy","immunotherapy","Melanoma (Skin)","Melanoma, Uveal","Ovarian Carcinoma","Uterine Carcinoma","Uterine Carcinosarcoma","Immatics","2026-05-12",{"date":68,"type":35},"2026-05-13",{"date":70,"type":35},"2019-05-14",{"date":72,"type":20},"2032-06",{"name":74,"class":42},"Immatics US, Inc.",21,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100565643","spatially-fractionated-radiation-treatment-for-gynaecological-cancers-100565643","NCT06644846","Spatially Fractionated Radiation Treatment for Gynaecological Cancers","A Prospective Study of Spatially Fractionated Radiation Treatment Using Rapid Rod Technique for Gynaecological Cancers","Inclusion Criteria:\n\n1. Patients with cervical cancer post EBRT, with expected suboptimal brachytherapy dose coverage due to-\n\n   1. Aberrant uterine or pelvic anatomy leading to difficulty in localization of the cervical OS or negotiation of the uterine canal accurately by two independent clinicians in up to two procedures.\n   2. Large residual disease at the time of brachytherapy with anticipated suboptimal target coverage either determined in clinic based on pre-brachytherapy imaging or at dose planning (e.g. figure 2).\n   3. Very narrow vaginal canal not accommodating even the smallest intracavitary or vaginal cylinder applicators.\n2. Patients with inoperable endometrial cancer not suitable for anaesthesia or have anticipated suboptimal coverage of target volume at brachytherapy as identified on pre-brachytherapy imaging obtained after EBRT.\n3. Patients with large pelvic recurrences after surgery and\u002For (chemo) radiation, not amenable to surgical salvage or brachytherapy after salvage EBRT due to reasons specified in item 1.\n4. Patients with contraindications to anaesthesia for brachytherapy with sufficient risk of on-table or post procedure adverse events.\n\nExclusion Criteria:\n\n1. Any pre-existing fistula in bladder or rectum.\n2. Pelvic prosthesis.\n3. Refusal to provide consent.","FEMALE","70 Years",{"count":86,"type":20},20,[88],"NA","This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.\n\nThe study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.",[91,92,28],"Cervical Cancer","Gynecologic Cancer",[94,30,95,96,97],"Cervical cancer","Recurrence","Spatially fractionated radiotherapy","Rapid rod","2026-02-18",{"date":100,"type":35},"2026-02-20",{"date":102,"type":35},"2024-10-04",{"date":104,"type":20},"2029-02-28",{"name":106,"class":107},"Tata Memorial Hospital","OTHER_GOV",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":132},"100394860","phase-1-pembrolizumab-ibrutinib-and-rituximab-in-pcnsl-100394860","NCT04421560","Pembrolizumab, Ibrutinib and Rituximab in PCNSL","A Phase Ib\u002FII Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory\u002FRelapsed Primary Central Nervous System Lymphoma (PCNSL)","Inclusion Criteria:\n\n* Participant must be able to understand and willing to sign a written informed consent document.\n* Participant must have signed and dated an IRB\u002FIEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.\n* Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.\n* Participant must be at least 18 years old on day of signing informed consent.\n* Subjects with pathologically confirmed PCNSL who progressed after CNS-directed therapy, primary refractory disease and relapsed disease are allowed. Participants should have evidence of R\u002FR disease on MRI or CSF cytology. Ocular only recurrences are allowed.\n* Subjects must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Life expectancy of \\>3 months (in the opinion of the investigator)\n* Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1\n* Must be able to tolerate lumbar puncture and\u002For Ommaya taps\n* Demonstrate adequate organ function as defined below, all screening labs should be performed within 28 days of treatment initiation.\n\n  * Hematology\n\n    * White Blood Count (WBC) ≥ 2 K\u002FμL\n    * Platelet count ≥ 100 K\u002FμL\n    * Absolute Neutrophil Count ≥ 1.5 K\u002FμL\n    * Hemoglobin \\> 9.0 g\u002FdL or ≥ 5.6 mmol\u002FL (Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks)\n  * Biochemistry\n\n    * Serum creatinine ≤1.5 x institutional ULN OR Measured or calculated creatinine clearance ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN (Creatinine clearance should be calculated per institutional standard)\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN(≤5 × ULN for participants with liver metastases)\n    * Total bilirubin (TBILI) ≤ 1.5 x institutional ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of \\\u003C 3.0 x institutional ULN) OR Direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN)\n  * Coagulation studies\n\n    * INR OR PT and Activated aPTT ≤1.5 × institutional ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n* Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test within 72 hours prior to registration.\n* Women in the following categories are not considered WOCBP:\n\n  * Premenarchal\n  * Premenopausal female with 1 of the following:\n\n    * Documented hysterectomy\n    * Documented bilateral salpingectomy\n    * Documented bilateral oophorectomy\n    * Note: Documentation can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.\n  * Postmenopausal female: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\n\n    * A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.\n  * Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.\n* Women of child-bearing potential (WOCBP; see definition above), must agree to use a highly effective method of contraception consistently and correctly as described below during study treatment and for 120 days after study discontinuation.\n\n  * 1\\. Highly Effective Contraceptive Methods That Are User Dependent a (Failure rate of \\\u003C 1% per year when used consistently and correctly.)\n\n    * a. Combined (estrogen- and progestogen- containing) hormonal contraception b, c\n\n      * i. Oral\n      * ii. Intravaginal\n      * iii. Transdermal\n      * iv. Injectable\n    * b. Progestogen-only hormonal contraception b, c\n\n      * i. Oral\n      * ii. Injectable\n  * 2\\. Highly Effective Methods That Have Low User Dependency (Failure rate of \\\u003C1% per year when used consistently and correctly)\n\n    * a. Progestogen- only contraceptive implant b, c\n    * b. Intrauterine hormone-releasing system (IUS) b\n    * c. Intrauterine device (IUD)\n    * d. Bilateral tubal occlusion\n    * e. Vasectomized partner: A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.\n    * f. Sexual abstinence: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.\n  * NOTES: Use should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical studies.\n\n    * Typical use failure rates are lower than perfect-use failure rates (i.e. when used consistently and correctly).\n    * If hormonal contraception efficacy is potentially decreased due to interaction with study treatment, condoms must be used in addition to the hormonal contraception during the treatment period and for at least during study treatment and for 120 days after study discontinuation after the last dose of study treatment.\n    * If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive implants are limited to those which inhibit ovulation.\n* Male participants must agree to use at least one of the following methods of contraception starting with the first dose of study therapy through 120 days after the last dose of therapy:\n\n  * 1\\. Be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent\n  * 2\\. Use a male condom plus partner use of a contraceptive method with a failure rate of \\\u003C1% per year as described in Eligibility criterion 3.1.13 when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant.\n  * a. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will not be eligible for admission into the study.\n\n* Patients who cannot undergo MRI brain\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40,CD137)\n* Previously progressed on ibrutinib or other BTK inhibitor use (patient who have previously received BTK inhibitor but not progressed while on it are allowed)\n* Patients with \\> Grade 2 intracranial hemorrhage\n* Concomitant warfarin, any other warfarin-derivative anticoagulant, vitamin K antagonists, within 7 days before starting treatment. Note: novel oral anticoagulants (NOACs, e.g., Apixaban, Dabigatran, Edoxaban, Rivaroxaban), low molecular weight heparin (LMWH) are allowed\n* Arterial thromboembolic events such as cerebrovascular accident within 3 months before the start of study treatment\n* Active autoimmune disease requiring immunosuppressive agents or steroids (prednisone \\>10mg or equivalent)\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Requires treatment for PCNSL with high dose systemic corticosteroids defined as dexamethasone \\> 4 mg\u002Fday or bioequivalent for \\>3 consecutive days within 2 weeks of registration\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks \\[could consider shorter interval for kinase inhibitors or other short half-life drugs\\] prior to dosing. OR 5 half-lives, whichever is shorter --- Note: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Participants with≤Grade 2 neuropathy may be eligible.\n* Patients who underwent major surgery ≤ 2 weeks before starting study treatment are excluded. If participant underwent major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting study treatment. Patients who plan to undergo surgery within 2 weeks of first dose of study treatment are excluded.\n* Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. Has received prior radiotherapy to CNS disease within 2 weeks of start of study treatment.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella,varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n* Has severe hypersensitivity (≥ Grade 3) to study agents and\u002For any of its excipients.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Patient is known to have an uncontrolled active systemic infection (\\>CTCAE grade 2) and recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug.\n* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association \\> Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification\n* Uncontrolled hypertension despite optimal medical management (per investigator's assessment).\n* Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin \\>8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of \\>8%.\n* Non-healing wound, ulcer or bone fracture.\n* Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia.\n* Unable to swallow capsules or disease significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction.\n* Concurrent administration of medications or foods that are moderate or strong inhibitors or strong inducers of cytochrome P450 (CYP) 3A4\u002F5 (need to be discontinued 2 weeks before starting study treatment)\n* Enzyme-inducing antiepileptic drugs (EIAED) need to be discontinued and switched to a non-EIAED 2 weeks prior to starting on trial drugs\n* Has known history of HIV\u002FAIDS\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n* Has a known history of active TB (Bacillus Tuberculosis)\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)\n* Patients who have undergone prior allogeneic stem cell transplant\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment",{"count":117,"type":20},37,[23,24],"This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).\n\nThe three drugs being used in the study are:\n\n* Pembrolizumab (MK3475)\n* Ibrutinib\n* Rituximab (or biosimilar)",[121,28,27,122],"Primary Central Nervous System Lymphoma","Relapsed Cancer",[121,28,27,122],{"date":100,"type":35},{"date":126,"type":35},"2020-08-01",{"date":128,"type":20},"2027-01-05",{"name":130,"class":131},"Dana-Farber Cancer Institute","OTHER",4,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100532119","phase-1-optimal-precision-therapies-to-customise-care-in-childhood-and-adolescent-cancer-100532119","NCT06208657","Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer","Inclusion Criteria:\n\n1. Patients must be diagnosed with a solid tumor, CNS tumor or lymphoma that has progressed despite standard therapy, or for which no effective standard therapy exists.\n2. Age \\\u003C21 years at inclusion; patients 21 years and older may be included after approval by the Study Chair if they have a pediatric type recurrent\u002Frefractory malignancy.\n3. Patients must be enrolled on a precision medicine study (i.e. PROFYLE, ZERO or equivalent as agreed with Study Chair).\n4. Patients enrolled in a Phase I cohort must have either evaluable or measurable disease.\n5. Patients enrolled in a Phase II cohort must have measurable disease. Evaluable and measurable disease are defined by standard imaging criteria for the patient's tumor type.\n6. Disease evaluations, laboratory tests, and other clinical assessments that are considered standard of care may be undertaken at the patient's local oncology treatment centre with results transferred to study site for evaluation.\n7. Performance status: Karnofsky performance status (for patients \\> 16 years of age) or Lansky play score (for patients ≤ 16 years of age) ≥ 50%.\n8. Life expectancy ≥ 6 weeks.\n9. Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer-directed therapy prior to enrolment.\n10. Adequate organ function.\n11. Able to comply with scheduled follow-up and with management of toxicity.\n12. Females of childbearing potential must have a negative serum or urine pregnancy test.\n13. Fertile males must agree to use adequate contraception during the study and following completion of treatment.\n14. Provide a signed and dated informed consent form.\n\nExclusion Criteria:\n\n1. Patients with symptomatic central nervous system (CNS) primary or metastatic tumours who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients on stable doses of corticosteroids for at least 7 days prior to receiving study drug may be included.\n2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, or malabsorption syndrome) - only for arms that include orally administered therapeutic agents.\n3. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality), unstable ischemia, congestive heart failure within 12 months of screening.\n4. Known active viral hepatitis or human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n5. Major surgery within 21 days of the first dose of investigational drug. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumour biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48-hour interval must be maintained before the first dose of the investigational drug is administered.\n6. Known hypersensitivity to any study drug or component of the formulation.\n7. Pregnant or nursing (lactating) females.\n8. Any other concomitant serious medical condition or organ dysfunction that in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the investigational drug(s).","0 Years","21 Years",{"count":142,"type":20},90,[23,24],"A companion platform trial to test novel targeted agents based on the patient's tumor profile.",[146,147,148,28,27],"Childhood Cancer","Childhood Solid Tumor","Childhood Brain Tumor",[150,151,152,153,154,155,156,157,158,159],"children","basket trial","platform study","pediatric","solid tumor","paediatric","solid tumour","CNS tumor","CNS tumour","lymphoma","2026-01-26",{"date":162,"type":35},"2026-01-28",{"date":164,"type":35},"2024-07-10",{"date":166,"type":20},"2035-12",{"name":168,"class":131},"Australian & New Zealand Children's Haematology\u002FOncology Group",14,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":108},"100378230","phase-2-cabozantinib-to-treat-recurrent-liver-cancer-post-transplant-100378230","NCT04204850","Cabozantinib to Treat Recurrent Liver Cancer Post Transplant","A Phase II Trial of Cabozantinib in the Treatment of Recurrent Hepatocellular Carcinoma Post Liver Transplant","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed hepatocellular carcinoma that has recurred.\n* Previously underwent a liver transplant as a curative treatment for hepatocellular carcinoma (HCC).\n* Not amenable to curative surgery or local treatment for recurrent disease.\n* Must have measurable disease.\n* No prior treatment with cabozantinib. May be systemic therapy naïve or have received up to 1 line of prior therapy for advanced HCC with sorafenib or lenvatinib.\n* Age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 01.\n* Life expectancy of \\>3 months.\n* Normal organ and marrow function.\n* Adequate cardiac function.\n* No evidence of active uncontrolled infection.\n* Understand and willing to sign written informed consent document.\n* Recovered from prior toxicities to \\\u003C grade 1.\n* Able to take oral medications.\n* Agree to use effective contraceptive methods until at least 30 days (for women) and 3 months (for men) after the last administration of study medication. Serum pregnancy test should be negative.\n\nExclusion Criteria:\n\n* Had systemic therapy or radiotherapy \\\u003C3 weeks.\n* Receiving any other investigational agents.\n* With known brain metastases unless stable for \\>3 months.\n* History of allergic reactions attributed to cabozantinib.\n* Has uncontrolled, significant intercurrent or recent illness:\n* Cardiovascular disorders\n* Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation\n* Major surgery within 2 months before randomization\n* Cavitating pulmonary lesion(s) or endobronchial disease (untreated)\n* Lesion invading a major blood vessel\n* Clinically significant bleeding risk \\\u003C3 months\n* Other clinically significant disorders:\n* Active infection requiring systemic treatment, known infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)-related illness\n* Serious non-healing wound\u002Fulcer\u002Fbone fracture\n* Malabsorption syndrome\n* Uncompensated\u002Fsymptomatic hypothyroidism\n* Requirement for hemodialysis or peritoneal dialysis\n* Pregnant women.\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures\n* Active hepatitis B or C in liver graft\n* Patients with a grade \\>= 2 elevated liver enzymes who are suspected of cellular rejection will undergo biopsy. Patients diagnosed with cellular rejection in the biopsy sample using the Banff schema are ineligible.\n* Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma\n* Moderate or severe ascites\n* Concomitant use of anticoagulants at therapeutic doses\n* Has a known history of prior invasive malignancy except if patient has undergone curative-intent therapy with no evidence of disease recurrence for 2 years prior to study entry.",{"count":86,"type":20},[24],"This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients.\n\nCabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) that are important in the development of cancer tumors.\n\nAll participants will receive cabozantinib until they are no longer receiving benefit from the study drug or they experience an intolerable side effect.",[181,28,182],"Hepatocellular Carcinoma","Liver Transplant","2025-12-02",{"date":185,"type":35},"2025-12-03",{"date":187,"type":35},"2020-08-07",{"date":189,"type":20},"2026-06-30",{"name":191,"class":131},"University Health Network, Toronto",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":199,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100593112","phase-1-personalized-neoantigen-peptide-vaccines-for-solid-tumors-100593112","NCT07002203","Personalized Neoantigen Peptide Vaccines for Solid Tumors","A Phase Ib Clinical Study of Personalized Neoantigen Peptide Vaccines for Solid Tumors","Inclusion Criteria:\n\n1. Age: 20 years or older.\n2. Language proficiency: Able to read and understand Thai clearly.\n3. Consent: Willing to provide informed consent and sign a participation agreement.\n4. Life expectancy: Estimated to be at least 6 months from the date of consent.\n5. Eligibility from prior research: Must have participated in the SQK01-002A research project and have tumor tissue confirmed as suitable for neoantigen peptide vaccine production.\n6. Performance status: ECOG performance status of 0-2 with stable organ function, no rapid disease progression, or impending organ failure.\n7. Cancer diagnosis: Clinically and pathologically confirmed cancer diagnosis, with supporting radiological evidence.\n8. Cancer stage-specific criteria:\n\n   i. Advanced cancer: Suitable for immune checkpoint inhibitors (ICIs) and shows resistance to prior therapies, with measurable lesions based on mRECIST1.1 criteria.\n\n   ii. Early-stage cancer: High recurrence risk despite prior surgery and\u002For radiotherapy, with no current adjuvant treatment standard.\n9. Laboratory parameters:\n\n   i. Lymphocyte count ≥ 800 cells\u002FμL. ii. Neutrophil count ≥ 1,500 cells\u002FμL. iii. Platelet count ≥ 75,000 cells\u002FμL. iv. AST ≤ 2.5 times the upper limit of normal (ULN). v. ALT ≤ 2.5 times ULN. vi. Total bilirubin ≤ 1.5 times ULN. vii. Serum creatinine ≤ 1.5 times ULN.\n10. Consent to Avoid Pregnancy or Causing Pregnancy Under the Following Criteria i. Female participants not of reproductive age, defined as having undergone a hysterectomy and\u002For bilateral oophorectomy, experiencing continuous menopause for more than 12 months, or being over 60 years of age.\n\nii. Female participants of reproductive age must undergo a pregnancy test and have a confirmed negative result during the preparation phase and before the first day of vaccination. They must also consent to using contraception with an efficacy rate greater than 99%, as recommended by the principal investigator, throughout the study duration, including the preparation phase and follow-up, and up to 120 days after the final treatment.\n\niii. Male participants must consent to using contraception with an efficacy rate greater than 99%, as recommended by the principal investigator, throughout the study duration, including the preparation phase and up to 120 days after the final treatment.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to peptide vaccines or related substances.\n2. Autoimmune disease history.\n3. Previous treatments that significantly suppress or impair immune function.\n4. Refusal of current standard-of-care treatment.\n5. Active brain or central nervous system metastases unless well-controlled with steroids ≤ 10 mg\u002Fday prednisolone.\n6. Presence of more than one active cancer type.\n7. Uncontrolled cardiac conditions, such as unstable angina or advanced heart failure (NYHA Class III\u002FIV).\n\n   i. Participants with pacemakers may be eligible if stabilized for at least 1 month before vaccination.\n8. Receipt of any other vaccines within 28 days before the first neoantigen peptide vaccine.\n9. Participation in another clinical trial.\n10. Use of immunosuppressive drugs or steroids \\> 10 mg\u002Fday prednisolone (except inhaled\u002Fintranasal corticosteroids).\n11. Pre-existing conditions that could compromise the efficacy or safety of the peptide vaccine.\n12. Pregnancy or breastfeeding.","20 Years",{"count":5,"type":20},[23,24],"This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is to help the patient's immune system recognize and attack their cancer.\n\nThe study will enroll adult patients (20 years or older) who have solid tumors that meet specific stage-related criteria. These include advanced cancers that are resistant to prior treatments and early-stage cancers at high risk of recurrence, where there are no standard adjuvant therapies available.\n\nParticipants will receive:\n\n* A personalized neoantigen peptide vaccine designed from the mutations in their tumor tissue.\n* Poly-ICLC (Hiltonol), a substance that stimulates the immune system.\n* An anti-PD-1 immune checkpoint inhibitor, a drug that helps the immune system stay active against cancer.\n\nThe vaccine and drugs will be given through multiple injections over several months. Blood samples and imaging will be used to monitor the immune response and how the cancer responds to treatment. Participants will be followed for up to 12 months.\n\nThis study does not include a placebo group. Every participant will receive the personalized vaccine along with the other therapies.\n\nThe primary objectives of this study are:\n\n1. To assess whether the treatment is safe and tolerable.\n2. To evaluate whether this approach helps control the cancer and can be combined with other standard treatments in the future.",[204,205,28,206,207],"Solid Tumors","Advanced Cancer","Neoantigen-Specific Immunotherapy","Personalized Cancer Vaccine","2025-11-27",{"date":210,"type":35},"2025-12-01",{"date":212,"type":35},"2024-03-01",{"date":214,"type":20},"2027-08",{"name":216,"class":42},"Seqker Biosciences, Inc.",2,{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100505013","phase-2-preventing-second-cancers-with-dostarlimab-100505013","NCT05855811","PREventing Second Cancers With DOSTARlimab","A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer","PREDOSTAR","Inclusion Criteria:\n\n* Male or female patient ≥18 years of age at time of informed consent form signature. Note - Patients with childhood first primary cancer (FPC) are eligible.\n* Patients with prior histologically proven primary solid tumors (any type), AJCC stage I, II or III or IV if M0, eligible to curative treatment. Note - Time between end of treatment for first cancer and randomisation must be \\\u003C6 months.\n* Patients with at least one risk factor for second primary cancer (SPC) including:\n* Exposure to exogenous risk factor : tobacco (\\>20YP) ≥ 10 years and still active at time of FPC diagnosis and\u002For Endogenous risk factors (genetic predisposition including for instance germ line mutations of p53 or BRCA genes, Lynch syndrome, or any mutations of genes known to be associated with higher risk of cancer according to current list from French National Cancer institute or HPV-related FPC.\n* Availability of FFPE tumor sample from FPC initial diagnosis for histological comparison in case\u002Fat time of SPC. Note - Histological report must be sent to the sponsor with archival FFPE tumor block within 14 days after randomisation.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or .\n* Adequate hematologic and end-organ function, defined by the following laboratory test results:\n* WBC ≥ 2.5 x 109\u002FL,\n* Hemoglobin ≥ 9.0 g\u002FdL. Patients may be transfused (\\> 2 weeks before randomisation) to meet this criterion,\n* Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL without granulocyte colony-stimulating factor support within 2 weeks before randomisation,\n* Platelets ≥ 100 x 109\u002FL,\n* Lymphocyte count ≥ 0.5 x 109\u002FL;\n* Serum creatinine clearance ≥30 mL\u002Fmin\u002F1.73m2 (MDRD or CKD-EPI formula - See Appendix) or serum creatinine ≤1.5 ULN\n* Serum bilirubin ≤ 1.5 × Upper Limit of Normal (ULN), with the following exception: Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled;\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 x ULN;\n* Prothrombin time\u002FINR ≤ 1.5, or, if patient is receiving therapeutic anticoagulation, prothrombin time\u002FINR \\\u003C 3.0\n* aPTT ≤ ULN OR, if patient is receiving therapeutic anticoagulation, aPTT must be \\\u003C 1.5 ULN. Note: Patient receiving therapeutic anticoagulation must be on stable dose.\n* Proteinuria by urine dipstick \\\u003C 2+ or 24-hour proteinuria ≤ 1.0 g.\n* Corrected QT interval (QTc) \\\u003C450msec (or QTc \\\u003C480msec for participants with bundle branch block).\n* Women patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy and agrees to use adequate contraception for up to 6 months after the final dose of dostarlimab.\n* Fertile men must agree to use an effective method of contraception during the study and for up to 6 months after the last dose of dostarlimab.\n* Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.\n* Patients must be covered by a medical insurance in country where applicable.\n\nExclusion Criteria:\n\n* Previous treatment with immunotherapy (any types) for cured first primary cancer.\n* Acute and ongoing toxicities from previous therapy that have not resolved to Grade ≤ 1, except for alopecia, neuropathy and lab values presented in inclusion criteria.\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomisation, or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to randomisation or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to randomisation, or anticipation of need for systemic immunosuppressive medication during study treatment; with the exceptions of intranasal, inhaled, or topical corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid.\n* Systemic immunostimulatory agents (including, but not limited to, interferons and IL-2) are prohibited within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisation.\n* Oral or IV antibiotics within 14 days of randomisation.\n* History of severe allergic or other hypersensitivity reactions to:\n\n  * chimeric or humanized antibodies or fusion proteins,\n  * biopharmaceuticals produced in Chinese hamster ovary cells, or\n  * any component of the dostarlimab formulation\n* Concurrent treatment with any approved or investigational anti-cancer treatment or participation in another clinical trial with therapeutic intent. Note - Hormonotherapy as part of standard of care is allowed.\n* History of autoimmune disease including (see Appendix 18.5 for a more comprehensive list of pre-existing autoimmune diseases and immune deficiencies and exceptions in the protocol.\n* Infectious diseases:\n\n  * active infection requiring IV antibiotics,\n  * severe infection within 4 weeks prior to randomisation, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia,\n  * active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \\[HBsAg\\] test at screening),\n  * active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA at screening,\n  * HIV infection,\n  * active tuberculosis,\n  * influenza vaccination should be given during influenza season. Patients must not receive live attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to randomisation or at any time during the study.\n* Significant cardiovascular disease: see details in the protocol.\n* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan.\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome).\n* Patient with FPC known to be at high risk of relapse defined as ≥ 70% relapse from FPC within 2 years.\n* Patient patients who are solid organ recipients.\n* Patient with primary cancer of unknown origin (CUP).\n* Pregnant or lactating women",{"count":19,"type":20},[24],"PredoSTAR is a multicenter, randomized, open-label phase II study proposed to patients at high risk of SPC and in whom the treatment of the FPC does not include immunotherapy. Dostarlimab treatment will be started within 6 months after the completion of treatment for localized FPC (i.e. after the end of last CT, RT cure or surgery with a wash-out period of 4 weeks before to start Dostarlimab). Eligible patients will be randomized (1:1) to receive:\n\n* Arm Dostarlimab : 4 intravenous (IV) injections of dostarlimab, Q3W or\n* Arm No treatment",[28,230,231],"Primary Cancer","Second Cancer","2024-07-12",{"date":234,"type":35},"2024-07-15",{"date":236,"type":35},"2023-07-26",{"date":238,"type":20},"2029-03-26",{"name":240,"class":131},"Centre Leon Berard",5,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":108},"100453785","safety-and-efficacy-of-sbrt-in-the-reirradiation-for-ultra-central-thoracic-malignant-tumors-100453785","NCT05189054","Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors","Inclusion Criteria:\n\n* Pathological diagnosis is malignant tumor.\n* The location of the target lesion belongs to the ultra-central type of chest.\n* The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm.\n* There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.\n* KPS\\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.\n\nExclusion Criteria:\n\n* Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.\n* The general condition is poor, and the expected survival time is less than 3 months.\n* Psychiatric patients or poor compliance, unable to cooperate to complete treatment.\n* For other reasons, the researcher believes that it is not suitable to participate in this trial.","80 Years",{"count":250,"type":20},40,"OBSERVATIONAL","The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for \"ultral-central\" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.",[254,255,256,28],"Stereotactic Body Radiation Therapy","Irradiation; Reaction","Thoracic Tumor","2023-12-22",{"date":259,"type":35},"2023-12-27",{"date":261,"type":35},"2022-05-01",{"date":263,"type":20},"2027-04-30",{"name":265,"class":131},"Peking University Third Hospital",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":276,"conditions":277,"keywords":286,"overallStatus":291,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":108},"100430796","phase-2-hyperthermia-enhanced-re-irradiation-of-loco-regional-recurrent-tumors-100430796","NCT04889742","Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors","HETERERO","Inclusion Criteria:\n\n* prior radiotherapy of the treatment side with a treatment dose \\> 30 Gray (Gy) EQD2 (calculated with alpha\u002Fbeta value of 9)\n* local\u002F regional \u002F or oligometastatic tumor recurrence. Maximum number of three macroscopic tumor lesions with at least one of them receiving prior radiotherapy\n* macroscopic tumor recurrence\n* side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine, cervical lymphnodes)\n* planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha\u002Fbeta value of 9)\n\nExclusion Criteria:\n\n* \\>3 macroscopic tumor lesion\n* brain metastases\n* recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic radiotherapy)\n* recurrence region is not amenable to hyperthermia (lung, liver, mediastinum)\n* contraindications for hyperthermia (serious cariovascular disease, ICD or larger implants at the treatment site)\n* psychiatric disorders that impede proper informed consent\n* serious comorbidities with very limited prognosis quo ad vitam",{"count":274,"type":20},110,[24],"This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.",[28,278,91,279,280,281,282,283,284,285],"Prostate Cancer","Anal Cancer","Sarcoma","Rectal Cancer","Neuroendocrine Tumors","Esophageal Cancer","Pancreas Cancer","Squamous Cell Carcinoma",[287,288,289,290],"re-irradiation","hyperthermia","local recurrence","hyperthermic","NOT_YET_RECRUITING","2023-12-19",{"date":294,"type":35},"2023-12-26",{"date":296,"type":20},"2024-05-10",{"date":298,"type":20},"2028-01",{"name":300,"class":131},"Charite University, Berlin, Germany"]